THERAPY DOSSIER · th-9d20802e1e53

Platelet-rich plasma, its total lipid extract and an endocannabinoid-enriched lipid fraction

Biologic · Biologic (autologous platelet-rich plasma and lipid fractions); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Biologic (autologous platelet-rich plasma and lipid fractions); not a ChEMBL entity
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01782885 ↗NAcompleted

Comparison of Acetaminophen and Platelet-rich Plasma Therapy for Knee Osteoarthritis

Knee Osteoarthritis

Enrolment: 543 · Results not recorded

NCT02285725 ↗NAcompleted

Microdrilling Surgery Augmented With Bone Marrow Aspirate, PRP and Hyaluronic Acid

Osteoarthritis Knee

Enrolment: 21 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23578218 ↗2013Reported benefit

Platelet-rich plasma exerts antinociceptive activity by a peripheral endocannabinoid-related mechanism.

MouseChemical/toxinIntrapaw injection

Model: Formalin injection into the paw producing acute inflammatory pain

Platelet-rich plasma, its lipid extract and the endocannabinoid-enriched fraction each produced potent antinociception against both early and late phases, and this was abolished by local CB1 and CB2 antagonists, indicating a peripheral endocannabinoid mechanism.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…